

Breast Cancer in Latinamerica and the Caribbean BCRF Project

INCTR

Sao Pablo, Brasil.

March 1st-4th 2007.

Dr. Andrés S. Guercovich

BCRF Project


- **First Step:** diagnosis of the situation about breast cancer in the region.
- **Second Step:** data analyzed in relationship with government regulations and international standards.
- **Third Step:** implementation of strategies to improve breast cancer care according to the previous steps analyzed.

Developing Countries

- All regions of Africa.
- Asia except Japan.
- South America
- Central America and the Caribbean.
- Melanesia, Micronesia and Polynesia

Modified from Kamangar

POPULATION GROWTH AND AGING: 2000-2050




% Under 65

% Over 65

Changed in a urban/rural distribution



Methodology



Breast Cancer Leader

- Medical Director from a main institute or cancer center in the country or region.
- Presidents or Past-presidents from scientific societies related with breast cancer care.
- Recognized specialists.
- Experts proposed by other opinion leaders.

Leader (n=95)




<i>Country</i>	<i>n</i>
Argentina	20
Bolivia	3
Brazil	10
Chile	7
Colombia	7
Honduras	4
Mexico	14
Panama	3
Paraguay	6
Peru	7
Uruguay	6
Venezuela	8

Breast Cancer Leaders

<i>Country</i>	<i>Number</i>	<i>Oncologist</i>	<i>Breast cancer surgeon</i>	<i>Radio-therapist</i>	<i>Oncologist surgeon</i>
Argentina	20	12	5	3	-
Bolivia	3		2	-	1
Brazil	10	7	1	1	1
Colombia	7	3	3	-	1
Chile	7	2	2	3	-
Honduras	4	3	-	-	1
Mexico	14	6	4	1	3
Panama	3	1	-	-	2
Paraguay	6	3	1	1	1
Peru	8	3	1	2	1
Uruguay	6	3	2	1	-
Venezuela	8	3	2	1	2
Total	95	46	22	13	13

Epidemiology

- Has your country laws about mamographic screening?



- Tumor registry:

National: Mexico, Uruguay, Paraguay, Panama and Venezuela.

Local: Argentina, Brazil, Peru, Colombia, Honduras and Chile.


Without: Bolivia.

Diagnosis

Origin of initial suspicious diagnosis


In your country

n=95



In your center

n=100



Diagnosis


First Specialist to consult with the suspect

In your country

n=95

Breast cancer
surgeon or
Gynecologist

83%




In your center

n=100

Breast cancer
surgeon or
Gynecologist

82%




Diagnosis

Time between mamographic or clinical suspicion and histopathological confirmation

In your country

n=95


% survey



in your center


n=100

% center



Diagnosis

Time between mamographic or clinical suspicion and histopathological confirmation according to type of institution




Stage at diagnosis

In your country


n=95

- < 25% of patients
- 25 - 49% of patients
- 50-75% of patients
- > 75% of patients



In your center

n=100




Diagnosis

Access to Mammography

In your country

n=95


% survey



In your center

n=100

% center




Diagnosis

Coverage of Mammography

In your country

n=95


% survey



In your center

n=100


% center



Diagnosis: Are the hormone receptors` markers available?

In your country


n=95



% surveys

In your center

n=100




% centers

Diagnosis: Are molecular samples available (Ki-67, Herb-2)?

In your country


n=95



% surveys

In your center

n=100



% centers


Lapse of time until treatment

From diagnosis to surgery or primary systemic treatment

In your country

n=95


% surveys



In your center

n=100

% centers



*QT:chemotherapy, **RT:radiotherapy


Lapse of time until treatment

From surgery to first treatment (hormonal, QT o RT*)*

In your country

n=95


% surveys



In your center

n=100


% centers



*QT:chemotherapy, **RT:radiotherapy

Treatment

Surgery as the first treatment, depending on stage



Who performs the surgery?


In your country

n=95

- < 25% of the patients
- 25 – 49% of the patients
- 50-75% of the patients
- > 75% of the patients
- Doesn't know

In your center

n=100




Treatment

Type of surgery: Mastectomy

In your country

n=95

% surveys




6.3% Doesn't know

In your center

n=100


% centers



Treatment: Is mastectomy performed in more than 10% of the cases when it is feasible to perform a lumpectomy?

In your country


n=95



% survey

In your center

n=100




% center

Mastectomy reasons in more than 10% of the feasibility cases of a lumpectomy


In your country

n=66



In your center

n=17



* Others: geographical difficulties to a correct follow-up.


Note: More than one is possible

Treatment

*Is Sentinel lymph node dissection performed
at your center?*

n=100

% center




Treatment

Is Sentinel lymph node dissection performed in your country?

Number and geographical distribution of the centers (public and private) where the sentinel node dissection is performed

% surveys

n=95



Chemotherapy pre-surgery – Stage I - II

in your country

n=95



in your center


n=100



Chemotherapy pre-surgery – Stage III A


in your country

n=95



in your center

n=100



Adjuvant (chemotherapy and hormonotherapy) Stage III


In your country

n=95



In your center

n=100




Costs of chemotherapy and hormonotherapy

In your country

n=95


% survey



In your center

n=100

% center




Treatment

Chemotherapy based on antraciclines

In your country


n=95



% survey

In your center

n=100



% center


Treatment

Proportion of patients treated with Tamoxifen

In your country

n=95


% survey



In your center

n=100

% center




Treatment election in patients with metastatic disease

In your country

n=95


% survey



In your center

n=100

% center




QT=chemotherapy, RT=radiotherapy, HT=hormonotherapy

Treatment: Palliative Care Availability and opiaceos indication

In your country

n=95


% survey



In your center

n=100

% center




Treatment: election of adjuvant treatment (Hormonotherapy and chemotherapy)

In your country

n=95


% survey



In your center

n=100

% center




Follow-up

Specialist who is responsible for the follow-up

In your country

n=95


% survey



In your center

n=100


% center




Clinical-epidemiological investigation

n=95

How Would you qualify the clinical-epidemiologic investigation development on breast cancer in your country ?



n=89




**Others: lack of political decision.

Note: more than one possible reply option.


Basic investigation

n=95

How would you qualify the development of basic investigation on breast cancer in your country ?



n=79




**Others: lack of politic decision.

Note: more than one possible reply option.

Clinical-epidemiological investigation

Where is it performed in your country?

n=95



Conclusion

◆ Problems:

- Absence of epidemiology data.
- Lack of political commitment.
- Low rate of mammographic screening.
- Hormone receptor and molecular markers not available for all patients.
- High percentage of mastectomy.
- Surgery done by gynecologist or general surgeon in an important number of cases.
- Clinical-epidemiological and basic-research are deficient.

Conclusion

◆ To stand out:

- Short interval gap between diagnosis and treatment.
- No great differences between the centers and countries for **therapeutical** standards.
- Adequate palliative care to treat patients.
(chemotherapy, hormonotherapy, morphine).
- Good level of education in specialists treating breast cancer.

Breast cancer leaders

Argentina: Bella Santiago, Block Carlos, Bustos Jorge, Capizzano Laura, Cazap Eduardo, Chacón Reinaldo, Del Castillo Rene Atilio, Gago Eduardo, Giacomi Nora, Jovtis Silvia, Langhi Mario, Leone Bernardo, Matwiejuc Mario Jorge, Mickiewicz Elizabeth, Morgado Cresta Carlos, Nuñez de Pierro Anibal, Reñe Juan, Taber Rogelio, Viniegra María. **Bolivia:** Fonseca Fernandez Lazaro, Paniagua Leon Carlos Felipe, Sitic Vargas Pablo. **Brazil:** Barrios Carlos Henrique, Froimtchuk Miguel, Gil Roberto, Menke Carlos Enrique, Murad André, Rufo de Freitas Junior, Salvajoli Joao Victor, Schwartzmann Gilberto, Simon Sergio, Vinholes Jeferson. **Colombia:** Caicedo José, Godoy Javier, Manni Raimundo, Ortiz Santa Cruz Carlos Alberto, Quintero Elías, Robledo José Fernando, Velásquez Andrés. **Chile:** Baeza Mario, Hepp Rodrigo, Muller Bettina, Orlandi Francisco, Orlandi Luis, Ramirez Augusto León, Vinés Eugenio. **Honduras:** Bejarano Cáceres Suyapa Aurora, Bulnes Molina Ricardo Ernesto, Maldonado Manuel, Segura Galdamez Ismael Arturo. **México:** Alaniz Camino Francisco, Barroso Bravo Sinuhé, Cervantes Sanchez María Guadalupe, De la Cruz Vargas Jhony Alberto, De la Garza Jaime, Erazo Aura, Gonzalez Danés Horacio, Lopez Granel Carlos, Mohar Alejandro, Muñoz Gonzalez David Eduardo, Ocampo LeRoyal Rolando, Rodríguez Vidal Carlos, Ruiz Martinez Hermilo, Sanchez Basurto Carlos. **Panama:** Lopez Roberto Ivan, Pereyra Ricardo, Villareal Anibal. **Paraguay:** Duarte Jose, Gauna Cinthia, Gomez Graciela, Guggiari Gustavo, Sforza Silvia. **Peru:** Chong Jorge Leon, Gomez Henry, Pinillos Ashton Luis Vicente, Vallejos Carlos, Velarde Raul, Vidaurre Tatiana. **Uruguay:** Aizen Bernardo, Garbino Carlos, Guericke Matilde, Kasdorf Pedro, Laviña Raul, Lombardo Karina. **Venezuela:** Ferri Nicasio Nino, Gomez Alvaro, Hernandez Gerardo, Khalek Yihad, Montesino Carlos, Rebolledo Morella, Torres Strauss Luis.